Towards Personalized Therapy in Pediatric Acute Lymphoblastic Leukemia: RAS Mutations and Prednisolone Resistance

Overview

Journal Haematologica

Specialty Hematology

Date 2014 Dec 7

PMID 25480501

Citations 19

Authors

Ingrid M Aries

Rosanna E van den Dungen

Marco J Koudijs

Edwin Cuppen

Emile Voest

Jan J Molenaar

Huib N Caron

Rob Pieters

Monique L den Boer

Affiliations

Soon will be listed here.

Citing Articles

Case report: single-cell transcriptome sequencing reveals the clonal origin of mature plasmacytoid dendritic cell proliferation in early T-cell precursor lymphoblastic leukemia.

Zhang L, Lu Y, Jiang J, Wu G Ann Hematol. 2025; .

PMID: 40085211 DOI: 10.1007/s00277-025-06301-5.

Spectrum of Genetic Mutations in Korean Pediatric Acute Lymphoblastic Leukemia.

Yoo J, Ahn A, Lee J, Jo S, Kim S, Lee J J Clin Med. 2022; 11(21).

PMID: 36362526 PMC: 9658397. DOI: 10.3390/jcm11216298.

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials.

Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Garcia-Chica J, Zhao R Haematologica. 2022; 108(4):969-980.

PMID: 36325893 PMC: 10071117. DOI: 10.3324/haematol.2022.281196.

Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Yu H, Du Y, Xu J, Zhang M Transl Cancer Res. 2022; 8(6):2485-2495.

PMID: 35117001 PMC: 8797845. DOI: 10.21037/tcr.2019.10.04.

T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.

Cordo V, Van der Zwet J, Cante-Barrett K, Pieters R, Meijerink J Blood Cancer Discov. 2021; 2(1):19-31.

PMID: 34661151 PMC: 8447273. DOI: 10.1158/2643-3230.BCD-20-0093.

References

Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M . Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood. 2004; 104(2):307-13. DOI: 10.1182/blood-2003-11-3876. View

Weston C, Balmanno K, Chalmers C, Hadfield K, Molton S, Ley R . Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene. 2003; 22(9):1281-93. DOI: 10.1038/sj.onc.1206261. View

Zhang J, Mullighan C, Harvey R, Wu G, Chen X, Edmonson M . Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118(11):3080-7. PMC: 3175785. DOI: 10.1182/blood-2011-03-341412. View

Zachos G, Zoumpourlis V, Sekeris C, Spandidos D . Binding of the glucocorticoid and estrogen-receptors to the human h-ras oncogene sequences. Int J Oncol. 2011; 6(3):595-600. DOI: 10.3892/ijo.6.3.595. View

Case M, Matheson E, Minto L, Hassan R, Harrison C, Bown N . Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008; 68(16):6803-9. DOI: 10.1158/0008-5472.CAN-08-0101. View

Rosen D, Minden M, Kornblau S, Cohen A, Gayko U, Putta S . Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS One. 2010; 5(10):e13543. PMC: 2965086. DOI: 10.1371/journal.pone.0013543. View

Mullighan C, Zhang J, Kasper L, Lerach S, Payne-Turner D, Phillips L . CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011; 471(7337):235-9. PMC: 3076610. DOI: 10.1038/nature09727. View

Styczynski J, Piatkowska M, Jaworska-Posadzy A, Czyzewski K, Kubicka M, Kolodziej B . Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia. Anticancer Res. 2012; 32(12):5495-9. View

Hayes T, Der C . Mutant and wild-type Ras: co-conspirators in cancer. Cancer Discov. 2013; 3(1):24-6. PMC: 3808242. DOI: 10.1158/2159-8290.CD-12-0521. View

10.

Paulsson K, Horvat A, Strombeck B, Nilsson F, Heldrup J, Behrendtz M . Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007; 47(1):26-33. DOI: 10.1002/gcc.20502. View

11.

Kaspers G, Pieters R, van Zantwijk C, van Wering E, van der Does-van den Berg A, Veerman A . Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood. 1998; 92(1):259-66. View

12.

Boisvert-Adamo K, Longmate W, Abel E, Aplin A . Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res. 2009; 7(4):549-56. PMC: 2689141. DOI: 10.1158/1541-7786.MCR-08-0358. View

13.

Aries I, Hansen B, Koch T, Van den Dungen R, Evans W, Pieters R . The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica. 2013; 98(12):1905-11. PMC: 3856966. DOI: 10.3324/haematol.2013.093823. View

14.

Driessen E, Van Roon E, Spijkers-Hagelstein J, Schneider P, De Lorenzo P, Valsecchi M . Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica. 2013; 98(6):937-44. PMC: 3669451. DOI: 10.3324/haematol.2012.067983. View

15.

Pui C, Mullighan C, Evans W, Relling M . Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood. 2012; 120(6):1165-74. PMC: 3418713. DOI: 10.1182/blood-2012-05-378943. View

16.

Johnson T, Li J, Beer D . Influence of the glucocorticoid receptor on c-fos inducibility in activated ras-containing mouse lung cells. Mol Carcinog. 1996; 17(2):70-7. DOI: 10.1002/(SICI)1098-2744(199610)17:2<70::AID-MC3>3.0.CO;2-X. View